BRD4 and pancreatic ductal adenocarcinoma: Increasing data show dual inhibition of HDACs and BRD4 as a promising strategy against many tumors, such as pancreatic ductal adenocarcinoma [28] and gallbladder cancer [29], however, the impacts of dual HDACs/BRD4 inhibition on virus-associated lymphomas including PEL remain unclear.